Answers are grounded in this paper and cite their sources.
Background: Over the last decade, researchers suggested that thalidomide may have the potential of great value in a subset of transfusion-dependent and non-transfusion-dependent thalassemia patients. This study aimed to observe and understand the response of thalidomide in transfusion-dependent Beta- Thalassaemic patients in particular. Materials and methods: This prospective observational study was conducted among 70 patients with β-thalassemia who require regular blood transfusions (BT) and received thalidomide for at least six months. Haemoglobin (Hb) levels before and three and six months after treatment with thalidomide were measured. Results: The mean age was 12.87±7.01 years and 54.3% were male. The mean (±SD) Hb level was 7.64 (±1.56), 8.11 (±1.62), and 8.48 (±1.80) g/dl at baseline, after three and six months of treatment with thalidomide, respectively. The median Hb changes was 0.84 g/dl and overall increase of Hb was 12.65% (interquartile range: -1.23% to 23.95%). Thirty-four (48.6%) patients did not receive any BT within the six-month treatment period and 32.9%, 15.7%, 2.9% received one-two, three-four, and five BT, respectively. Nine (12.9%) patients had raised serum SGPT levels (>56 U/L) after six months. Conclusion: Treatment with thalidomide for six months significantly increases Hb level and reduces BT in transfusion-dependent β-thalassemia patients.
No takes yet. Share an insight, caveat, or question.
Munira et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: